Based on the key indicators related to Minerva Neurosciences' liquidity, profitability, solvency, and operating efficiency, Minerva Neurosciences may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter. At this time, Minerva Neurosciences' Property Plant Equipment is fairly stable compared to the past year. Other Liabilities is likely to climb to about 89 M in 2024, despite the fact that Net Debt is likely to grow to (38.9 M). Key indicators impacting Minerva Neurosciences' financial strength include:
The essential information of the day-to-day investment outlook for Minerva Neurosciences includes many different criteria found on its balance sheet. An individual investor should monitor Minerva Neurosciences' cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Minerva Neurosciences.
Net Income
(31.51 Million)
Minerva
Select Account or Indicator
Market Cap
Enterprise Value
Ptb Ratio
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Average Payables
Capex To Depreciation
Pb Ratio
Free Cash Flow Per Share
Roic
Net Income Per Share
Payables Turnover
Cash Per Share
Pocfratio
Interest Coverage
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Intangibles To Total Assets
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Graham Number
Shareholders Equity Per Share
Debt To Equity
Capex Per Share
Graham Net Net
Interest Debt Per Share
Debt To Assets
Enterprise Value Over E B I T D A
Short Term Coverage Ratios
Price Earnings Ratio
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Ebt Per Ebit
Effective Tax Rate
Company Equity Multiplier
Long Term Debt To Capitalization
Total Debt To Capitalization
Return On Capital Employed
Debt Equity Ratio
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Net Income Per E B T
Cash Ratio
Cash Flow Coverage Ratios
Price To Book Ratio
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Debt Ratio
Cash Flow To Debt Ratio
Return On Assets
Price Fair Value
Return On Equity
Change In Cash
Stock Based Compensation
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Other Non Cash Items
Capital Expenditures
Total Cash From Operating Activities
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Other Cashflows From Financing Activities
Sale Purchase Of Stock
Investments
Net Borrowings
Total Cashflows From Investing Activities
Depreciation
Cash And Cash Equivalents Changes
Cash Flows Other Operating
Change To Operating Activities
Other Cashflows From Investing Activities
Change To Netincome
Change To Liabilities
Total Assets
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Net Debt
Retained Earnings
Cash
Cash And Short Term Investments
Common Stock Total Equity
Common Stock Shares Outstanding
Liabilities And Stockholders Equity
Other Current Assets
Other Stockholder Equity
Total Liab
Total Current Assets
Common Stock
Short Long Term Debt Total
Property Plant And Equipment Net
Accounts Payable
Non Current Assets Total
Non Currrent Assets Other
Other Assets
Good Will
Non Current Liabilities Total
Property Plant And Equipment Gross
Short Term Debt
Intangible Assets
Property Plant Equipment
Other Liab
Net Tangible Assets
Retained Earnings Total Equity
Short Term Investments
Capital Surpluse
Deferred Long Term Liab
Short Long Term Debt
Non Current Liabilities Other
Net Invested Capital
Net Working Capital
Capital Stock
Depreciation And Amortization
Interest Expense
Selling General Administrative
Other Operating Expenses
Operating Income
Ebit
Research Development
Ebitda
Total Operating Expenses
Income Before Tax
Total Other Income Expense Net
Income Tax Expense
Gross Profit
Net Income From Continuing Ops
Cost Of Revenue
Non Operating Income Net Other
Net Income Applicable To Common Shares
Interest Income
Net Interest Income
Reconciled Depreciation
Probability Of Bankruptcy
Understanding current and past Minerva Neurosciences Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Minerva Neurosciences' financial statements are interrelated, with each one affecting the others. For example, an increase in Minerva Neurosciences' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Minerva Neurosciences' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Minerva Neurosciences. Check Minerva Neurosciences' Beneish M Score to see the likelihood of Minerva Neurosciences' management manipulating its earnings.
Minerva Neurosciences Stock Summary
Minerva Neurosciences competes with Reviva Pharmaceuticals, Cognition Therapeutics, Transcode Therapeutics, Kodiak Sciences, and Zura Bio. Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Minerva Neurosciences, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts. Minerva Neuroscie operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 9 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Comparative valuation techniques use various fundamental indicators to help in determining Minerva Neurosciences's current stock value. Our valuation model uses many indicators to compare Minerva Neurosciences value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Minerva Neurosciences competition to find correlations between indicators driving Minerva Neurosciences's intrinsic value. More Info.
Minerva Neurosciences is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Minerva Neurosciences' Return On Equity is fairly stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Minerva Neurosciences by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Minerva Neurosciences Systematic Risk
Minerva Neurosciences' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Minerva Neurosciences volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on Minerva Neurosciences correlated with the market. If Beta is less than 0 Minerva Neurosciences generally moves in the opposite direction as compared to the market. If Minerva Neurosciences Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Minerva Neurosciences is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Minerva Neurosciences is generally in the same direction as the market. If Beta > 1 Minerva Neurosciences moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Minerva Neurosciences Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Minerva Neurosciences' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Minerva Neurosciences growth as a starting point in their analysis.
Minerva Neurosciences November 29, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Minerva Neurosciences help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Minerva Neurosciences. We use our internally-developed statistical techniques to arrive at the intrinsic value of Minerva Neurosciences based on widely used predictive technical indicators. In general, we focus on analyzing Minerva Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Minerva Neurosciences's daily price indicators and compare them against related drivers.
When running Minerva Neurosciences' price analysis, check to measure Minerva Neurosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Minerva Neurosciences is operating at the current time. Most of Minerva Neurosciences' value examination focuses on studying past and present price action to predict the probability of Minerva Neurosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Minerva Neurosciences' price. Additionally, you may evaluate how the addition of Minerva Neurosciences to your portfolios can decrease your overall portfolio volatility.